IN8BIO, Inc.
INAB1.990USD
+0.090+4.74%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
9.13MMarket Cap
LossP/E TTM
More Details of IN8BIO, Inc. Company
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
IN8BIO, Inc. Info
Ticker SymbolINAB
Company nameIN8bio Inc
IPO dateNov 12, 2020
CEOHo (William T)
Number of employees18
Security typeOrdinary Share
Fiscal year-endNov 12
AddressEmpire State Building
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10118
Phone16466006438
Websitehttps://www.in8bio.com
Ticker SymbolINAB
IPO dateNov 12, 2020
CEOHo (William T)
Company Executives of IN8BIO, Inc.
Name
Name/Position
Position
Shareholding
Change
Mr. Peter C. Brandt
Mr. Peter C. Brandt
Independent Director
Independent Director
98.69K
+72464.00%
Dr. Corinne Epperly
Dr. Corinne Epperly
Independent Director
Independent Director
2.73K
--
Ms. Luba Greenwood
Ms. Luba Greenwood
Independent Director
Independent Director
261.00
--
Mr. William T. Ho
Mr. William T. Ho
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Lawrence S. Lamb, Ph.D.
Dr. Lawrence S. Lamb, Ph.D.
Co-Founder, Executive Vice President, Chief Scientific Officer
Co-Founder, Executive Vice President, Chief Scientific Officer
--
--
Mr. Patrick Mccall, CPA
Mr. Patrick Mccall, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alan S. Roemer
Mr. Alan S. Roemer
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Kate Rochlin, Ph.D.
Dr. Kate Rochlin, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Emily Wang Fairbairn
Ms. Emily Wang Fairbairn
Independent Director
Independent Director
--
--
Dr. Jeremy R. Graff, Ph.D.
Dr. Jeremy R. Graff, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Peter C. Brandt
Mr. Peter C. Brandt
Independent Director
Independent Director
98.69K
+72464.00%
Dr. Corinne Epperly
Dr. Corinne Epperly
Independent Director
Independent Director
2.73K
--
Ms. Luba Greenwood
Ms. Luba Greenwood
Independent Director
Independent Director
261.00
--
Mr. William T. Ho
Mr. William T. Ho
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Lawrence S. Lamb, Ph.D.
Dr. Lawrence S. Lamb, Ph.D.
Co-Founder, Executive Vice President, Chief Scientific Officer
Co-Founder, Executive Vice President, Chief Scientific Officer
--
--
Mr. Patrick Mccall, CPA
Mr. Patrick Mccall, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Jan 2
Updated: Fri, Jan 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fairbairn Emily Wang
14.71%
683 Capital Management LLC
14.69%
Bios Equity Partners, LP.
5.81%
Franklin Advisers, Inc.
3.85%
Ho (William Tai Wei)
2.63%
Other
58.30%
Shareholders
Shareholders
Proportion
Fairbairn Emily Wang
14.71%
683 Capital Management LLC
14.69%
Bios Equity Partners, LP.
5.81%
Franklin Advisers, Inc.
3.85%
Ho (William Tai Wei)
2.63%
Other
58.30%
Shareholder Types
Shareholders
Proportion
Individual Investor
20.86%
Hedge Fund
18.86%
Venture Capital
6.07%
Investment Advisor/Hedge Fund
5.85%
Corporation
2.18%
Investment Advisor
1.02%
Research Firm
0.53%
Other
44.63%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
54
1.59M
32.33%
+555.38K
2025Q3
51
760.78K
16.42%
-113.60K
2025Q2
62
913.62K
26.39%
-147.96K
2025Q1
67
7.37M
36.64%
+2.95M
2024Q4
64
40.67M
56.11%
+11.42M
2024Q3
66
26.31M
53.00%
+3.73M
2024Q2
66
26.43M
54.24%
+1.59M
2024Q1
62
24.15M
55.92%
+314.96K
2023Q4
58
23.08M
53.43%
+4.41M
2023Q3
55
17.49M
62.06%
+5.54M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fairbairn Emily Wang
725.56K
15.66%
+721.59K
+18185.28%
Dec 22, 2025
683 Capital Management LLC
724.64K
15.64%
+724.64K
--
Dec 22, 2025
Bios Equity Partners, LP.
286.66K
6.19%
--
--
Dec 22, 2025
Franklin Advisers, Inc.
189.89K
4.1%
--
--
Sep 30, 2025
Ho (William Tai Wei)
129.86K
2.8%
+36.23K
+38.70%
Dec 22, 2025
Transcend Partners Opportunity Fund LLC
107.42K
2.32%
--
--
Jun 30, 2025
Brandt (Peter C)
98.69K
2.13%
+72.46K
+276.30%
Dec 22, 2025
Two Sigma Investments, LP
95.20K
2.05%
+95.20K
--
Sep 30, 2025
Alyeska Investment Group, L.P.
82.48K
1.78%
--
--
Sep 30, 2025
Stonepine Capital Management, LLC
78.72K
1.7%
-80.71K
-50.62%
Dec 19, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jun 04, 2025
Merger
30→1
Date
Ex-dividend Date
Type
Ratio
Jun 04, 2025
Merger
30→1
